Akums Drugs & Pharmaceuticals, India’s largest CDMO, has reported a strong set of financial results for Q4 and the full year FY26, marked by robust margin expansion, sharp profit growth, and steady operational momentum across its core businesses.

 

The company’s performance in Q4 FY26 reflected improving execution and rising efficiency in its domestic CDMO operations, which continued to anchor overall growth.

 

For Q4 FY26, operating revenue stood at Rs. 1,158 crore, up 9.7% year-on-year from Rs. 1,056 crore in Q4 FY25. Adj EBITDA jumped 61.6% to Rs. 152 crore from Rs. 94 crore, with margins expanding sharply to 13.1% from 8.9%. Adj PAT rose to Rs. 83 crore, compared to Rs. 35 crore a year earlier, marking a 135% year-on-year surge, while PAT margins improved to 7.0% from 3.3%.

 

For the full year FY26, revenue increased to Rs. 4,359 crore, up 5.9% from Rs. 4,118 crore in FY25. Adj EBITDA rose 13.3% to Rs. 522 crore, and Adj PAT climbed 27.3% to Rs. 276 crore, underscoring sustained profitability gains through the year.

 

The CDMO segment remained the primary growth engine. Q4 CDMO revenue rose to Rs. 952 crore from Rs. 840 crore in Q4 FY25, while CDMO EBITDA surged 54.9% to Rs. 137 crore. Margins improved to 14.4% from 10.6%, supported by stronger customer engagement, better capacity utilisation, and disciplined execution.

 

The Domestic Branded Formulations business remained largely stable in Q4 at Rs. 102 crore versus Rs. 104 crore a year earlier, while EBITDA held steady at Rs. 22 crore. For FY26, the segment delivered improved profitability with revenue rising 2.9% to Rs. 446 crore and EBITDA increasing 17% to Rs. 90 crore.

 

The International Branded Formulations business saw a slight dip in quarterly revenue to Rs. 36 crore from Rs. 40 crore, though full-year revenue remained stable at Rs. 143 crore. EBITDA, however, improved significantly by 32.3% year-on-year to Rs. 36 crore, indicating stronger operational efficiency.

 

Trade generics showed a turnaround, reporting a positive EBITDA of Rs. 1.4 crore in Q4 FY26. For FY26, the segment reduced losses sharply to Rs. 10 crore from Rs. 28 crore in FY25, reflecting improving unit economics.

 

The API business remained under pressure due to pricing challenges. Revenue in Q4 fell to Rs. 41 crore from Rs. 50 crore, with an operating loss of Rs. 12 crore. For the full year, API losses narrowed slightly to Rs.b40 crore from Rs. 44 crore.

 

Despite segmental headwinds, Akums made notable strategic progress toward global expansion during FY26. 

 

The company recorded its first commercial supply of formulations to Europe, secured EU GMP certifications for Oral Solids and Oral Liquids facilities, and received UK MHRA approval for Rivaroxaban. Its injectable plant received Brazil ANVISA approval, while the ground-breaking of a pharmaceutical facility in Zambia marked a key international milestone.

 

On shareholder returns, the Board recommended a final dividend of Re. 1 per equity share along with a special dividend of Rs. 2 per equity share.

 

Commenting on performance, Sanjeev Jain, Managing Director, Akums Drugs & Pharmaceuticals, said: “FY26 has been a year of steady progress for Akums. We delivered healthy growth in revenue and profitability while continuing to build capabilities for the long term. 

 

"Our regulatory milestones, international developments and strong domestic performance reflect our focus on building Akums as a global pharmaceutical company and a trusted partner for our clients.”

 

Sandeep Jain, Managing Director, Akums Drugs & Pharmaceuticals, added: “The Q4FY26 and full year performance showed improvement across key operational parameters. Our CDMO business continued to perform well as we remain focused on better capacity utilisation, cost discipline and future growth. We are working on multiple digitization and automation initiatives which will deliver long-term value for the organization.”

 

Overall, while performance remained strong, the API segment continued to face pricing pressure. The company reiterated its focus on portfolio optimisation, cost control, and operational efficiency to support sustainable growth ahead.